AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
omacetaxine mepesuccinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4677 | 26833-87-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.80 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.96 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.80 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PRKDC,SYK,TEK,TGFBR1,ZAP70 | 26 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 26, 2012 | FDA | IVAX INTL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 387.09 | 50.52 | 90 | 718 | 53501 | 90574138 |
| Platelet count decreased | 94.71 | 50.52 | 38 | 770 | 136931 | 90490708 |
| Bone marrow failure | 61.15 | 50.52 | 19 | 789 | 32202 | 90595437 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 457.47 | 51.39 | 115 | 783 | 40346 | 42580091 |
| Platelet count decreased | 68.39 | 51.39 | 40 | 858 | 138541 | 42481896 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 826.15 | 48.38 | 202 | 1367 | 94138 | 110493592 |
| Platelet count decreased | 143.00 | 48.38 | 68 | 1501 | 230375 | 110357355 |
| Granulocyte count decreased | 68.88 | 48.38 | 15 | 1554 | 3959 | 110583771 |
| Bone marrow failure | 68.36 | 48.38 | 27 | 1542 | 57821 | 110529909 |
| Nausea | 66.59 | 48.38 | 84 | 1485 | 1235606 | 109352124 |
| White blood cell count decreased | 66.59 | 48.38 | 41 | 1528 | 229349 | 110358381 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XX40 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitor |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
Related Drugs by ATC class:
L01XX Other antineoplastic agents 33 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.86 | acidic |
| pKa2 | 8.15 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.5MG/VIAL | SYNRIBO | TEVA PHARMS INTL | N203585 | Oct. 26, 2012 | DISCN | POWDER | SUBCUTANEOUS | 6987103 | Oct. 26, 2026 | TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML) |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D08956 | KEGG_DRUG |
| 4031782 | VUID |
| N0000186058 | NUI |
| 4031782 | VANDF |
| 4031814 | VANDF |
| CHEBI:71019 | CHEBI |
| HMT | PDB_CHEM_ID |
| CHEMBL46286 | ChEMBL_ID |
| 7454 | IUPHAR_LIGAND_ID |
| 8885 | INN_ID |
| DB04865 | DRUGBANK_ID |
| 6FG8041S5B | UNII |
| 1356689 | RXNORM |
| 194347 | MMSL |
| 27023 | MMSL |
| d07573 | MMSL |
| 009753 | NDDF |
| 421021001 | SNOMEDCT_US |
| 421815001 | SNOMEDCT_US |
| C0062941 | UMLSCUI |
| C3528000 | UMLSCUI |
| D000077863 | MESH_DESCRIPTOR_UI |
| 285033 | PUBCHEM_CID |
| 24316-19-6 | SECONDARY_CAS_RN |
| 65305 | PUBCHEM_CID |
| 84MI6OYN4Z | UNII |
| 6FG8041S5B | INXIGHT DRUGS |
| 84MI6OYN4Z | INXIGHT DRUGS |
Pharmaceutical products:
None